Renal cell carcinoma with fibromyomatous stroma, recognized as a provisional entity in the current 2022 World Health Organization classification of renal neoplasms, is rare. Recent evidence suggests recurrent alterations in the mTOR pathway, supporting its recognition as a distinct entity. Herein, we report 2 renal cell carcinomas with fibromyomatous stroma with MTOR mutations occurring in 62- and 72-year-old women and review the literature to support its recognition as a distinct entity, focusing on the characteristic morphology, immunohistochemical staining patterns as well as genetic alterations.
ParillaMAlikhanMAl-KawaazM, et al.Genetic underpinnings of renal cell carcinoma with leiomyomatous stroma. Am J Surg Pathol. 2019;43(8):1135-1144. 2019/04/16. DOI: https://doi.org/10.1097/PAS.0000000000001255
3.
PeckovaKGrossmannPBulimbasicS, et al.Renal cell carcinoma with leiomyomatous stroma–further immunohistochemical and molecular genetic characteristics of unusual entity. Ann Diagn Pathol. 2014;18(5):291-296. 2014/09/02. DOI: https://doi.org/10.1016/j.anndiagpath.2014.08.004.
4.
PeterssonFMartinekPVanecekT, et al.Renal cell carcinoma with leiomyomatous stroma: a group of tumors with indistinguishable histopathologic features, but 2 distinct genetic profiles: next-generation sequencing analysis of 6 cases negative for aberrations related to the VHL gene. Appl Immunohistochem Mol Morphol. 2018;26(3):192-197. 2017/10/31. DOI: https://doi.org/10.1097/PAI.0000000000000410.
5.
ShahRBStohrBATuZJ, et al.Renal cell carcinoma with leiomyomatous stroma harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am J Surg Pathol. 2020;44(5):571-581. 2019/12/19. DOI: https://doi.org/10.1097/PAS.0000000000001422.
6.
WilliamsonSRChengLEbleJN, et al.Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity. Mod Pathol. 2015;28(2):279-294. 20140905. DOI: https://doi.org/10.1038/modpathol.2014.105.
WHO. Urinary and Male Genital Tumours. 5th ed. International Agency for Research on Cancer; 2022.
9.
KapurPBrugarolasJTrpkovK. Recent advances in renal tumors with TSC/mTOR pathway abnormalities in patients with tuberous sclerosis complex and in the sporadic setting. Cancers (Basel). 2023;15(16):4043. DOI: https://doi.org/10.3390/cancers15164043.
10.
LiHArganiPHalper-StrombergE, et al.Positive GPNMB immunostaining differentiates renal cell carcinoma with fibromyomatous stroma associated with TSC1/2/MTOR alterations from others. Am J Surg Pathol. 2023;47(11):1267-1273. DOI: https://doi.org/10.1097/PAS.0000000000002117.
11.
SiegmundSEAl-ObaidyKITsaiHK, et al.Concordance of MTOR pathway mutations and the diagnosis of renal low-grade oncocytic tumor (LOT). Int J Surg Pathol. 2023:10668969231178032. 2023/06/26. DOI: https://doi.org/10.1177/10668969231178032.
12.
WilliamsonSRCardiliLWhiteleyLJ, et al.Sclerosing TSC1 mutated renal cell carcinoma: an unusual pattern mimicking MITF family translocation renal cell carcinoma. Genes Chromosomes Cancer. 2020;59(10):591-594. 20200613. DOI: https://doi.org/10.1002/gcc.22860.
